ImmunoPrecise Antibodies Reports Record Fiscal Year 2025 Results

ImmunoPrecise Antibodies ( (IPA) ) has provided an update.

ImmunoPrecise Antibodies Ltd. announced record financial results for the fiscal year ending April 30, 2025, with a revenue of $24.5 million and a notable increase in gross margins. The company achieved significant milestones, including a strategic partnership for cancer treatment development and advancements in AI-driven platforms, positioning itself strongly in the biotech industry. The company’s BioStrand segment showed remarkable growth, contributing to improved financial performance and highlighting the commercial validation of its technology.

The most recent analyst rating on (IPA) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on ImmunoPrecise Antibodies stock, see the IPA Stock Forecast page.

Spark’s Take on IPA Stock

According to Spark, TipRanks’ AI Analyst, IPA is a Neutral.

ImmunoPrecise Antibodies’ overall financial performance is weak, with persistent losses and cash flow issues. However, recent earnings call highlights, such as strategic partnerships and financial strengthening, provide a positive outlook. Technical indicators suggest moderate positive momentum, but valuation remains a challenge due to ongoing losses.

To see Spark’s full report on IPA stock, click here.

More about ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd. is a bio-native AI company that operates at the intersection of technology and next-generation drug discovery. The company focuses on developing AI-driven therapeutic solutions and has a significant market focus on antibody discovery and therapeutic design.

Average Trading Volume: 2,406,014

Technical Sentiment Signal: Buy

Current Market Cap: $92.45M

For detailed information about IPA stock, go to TipRanks’ Stock Analysis page.